SCHEMBL14921130

SCHEMBL14921130

OCC(F)(F)c1ncc(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ GRIN2B Q13224 1/20 0.38
▸ PLAU P00749 1/20 0.37
▸ CYP2C9 P11712 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ APEX1 P27695 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HTT P42858 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ XBP1 P17861 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ TRPM8 Q7Z2W7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17315778 0.84 GRIN2B (0.39) GRIN2BHTTALDH1A1HSD17B10GAA
SCHEMBL16552187 0.82 PLAU (0.40) PLAUHTTALDH1A1GAA
SCHEMBL14921239 0.82 ALDH1A1 (0.53) L3MBTL1PLAUSMN1; SMN2HTTALDH1A1
SCHEMBL15999652 0.82 ALDH1A1 (0.33) L3MBTL1PLAUHTTALDH1A1GAA
SCHEMBL17325379 0.81 GRIN2B (0.38) LMNAL3MBTL1GRIN2BPLAUCYP2C9
SCHEMBL14920915 0.81 GRIN2B (0.40) LMNAL3MBTL1GRIN2BPLAUCYP2C9
SCHEMBL17964135 0.78 HTT (0.43) LMNAL3MBTL1GRIN2BPLAUCYP2C9
SCHEMBL20271591 0.77 HTT (0.36) LMNASMN1; SMN2HTTALDH1A1GAA
SCHEMBL21994824 0.75 CYP2C9 (0.37) LMNAL3MBTL1GRIN2BPLAUCYP2C9
SCHEMBL14921080 0.73 LMNA (0.41) LMNAL3MBTL1PLAUCYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3152213-B1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS CAYMAN LTD (KY) 2018-10-31 — — EP disclosed
US-10030026-B2 Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-07-24 — — US disclosed
US-10030026-B2 Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-07-24 — — US disclosed
US-10030026-B2 Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-07-24 — — US disclosed
US-20170101412-A1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2017-04-13 — — US disclosed
US-20170101412-A1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2017-04-13 — — US disclosed
US-20170101412-A1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2017-04-13 — — US disclosed
EP-3152213-A1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS Rugen Holdings (Cayman) Limited (KY) 2017-04-12 — — EP disclosed
US-9301526-B2 Compounds with nematicidal activity BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-04-05 — — US disclosed
US-9301526-B2 Compounds with nematicidal activity BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-04-05 — — US disclosed
US-20140249149-A1 Compounds with Nematicidal Activity BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-04 — — US disclosed
CN-104023540-A COMPOUNDS WITH NEMATICIDAL ACTIVITY BAYER IP GMBH 2014-09-03 — — CN disclosed
EP-2606727-A1 Compounds with nematicidal activity Bayer CropScience AG (DE) 2013-06-26 — — EP disclosed
EP-2606727-A1 Compounds with nematicidal activity Bayer CropScience AG (DE) 2013-06-26 — — EP disclosed
EP-2606728-A1 Compounds with nematicidal activity Bayer CropScience AG (DE) 2013-06-26 — — EP disclosed
EP-2606728-A1 Compounds with nematicidal activity Bayer CropScience AG (DE) 2013-06-26 — — EP disclosed
WO-2013064461-A2 COMPOUNDS WITH NEMATICIDAL ACTIVITY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-10 — — WO disclosed
WO-2013064460-A1 COMPOUNDS WITH NEMATICIDAL ACTIVITY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-10 — — WO disclosed
WO-2013064460-A1 COMPOUNDS WITH NEMATICIDAL ACTIVITY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-10 — — WO disclosed
WO-2013064461-A2 COMPOUNDS WITH NEMATICIDAL ACTIVITY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030026-B2 Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists GRIN1, GRIN2A, GRIN2B LMNA 4634/4885L3MBTL1 3260/4885GRIN2B 3/4885
US-20140249149-A1 Compounds with Nematicidal Activity ACHE, NAAA, TUBA3C LMNA 1201/4885L3MBTL1 1501/4885GRIN2B 2183/4885
US-20170101412-A1 DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS GRIN1, GRIN2A, GRIN2B LMNA 4634/4885L3MBTL1 3260/4885GRIN2B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback